Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Healthy return on equity of 17.9%
Concerns0
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ23.11 K Cr | β | βΉ5.35 K Cr | β | β | 18.5% | 18.6% | 23.2% |
| Mar 2024 | βΉ19.48 K Cr | β | βΉ4.34 K Cr | β | β | 17.9% | 14.9% | 66.2% |
| Mar 2023 | βΉ16.96 K Cr | β | βΉ2.61 K Cr | β | β | 12.8% | 17.8% | 61.0% |
| Mar 2022 | βΉ14.40 K Cr | β | βΉ1.62 K Cr | β | β | 8.9% | 7.9% | -25.8% |
| Mar 2021 | βΉ13.35 K Cr | β | βΉ2.19 K Cr | β | β | 12.9% | 12.6% | -25.6% |
| Mar 2020 | βΉ11.85 K Cr | β | βΉ2.94 K Cr | β | β | 19.3% | 11.5% | 130.1% |
| Mar 2019 | βΉ10.63 K Cr | β | βΉ1.28 K Cr | β | β | 10.1% | 13.5% | 125.2% |
| Mar 2018 | βΉ9.36 K Cr | β | βΉ567.00 Cr | β | β | 4.8% | -3.7% | -59.0% |
| Mar 2017 | βΉ9.72 K Cr | β | βΉ1.38 K Cr | β | β | 11.9% | -5.6% | 0.7% |
| Mar 2016 | βΉ10.29 K Cr | β | βΉ1.37 K Cr | β | β | 11.4% | 2.8% | -18.2% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 23,006 |
| Total Expenses | 16,053 |
| EBIT / Operating Profit | 6,953 |
| OPM % | 30% |
| Other Income | 1,412 |
| Finance Costs | 127 |
| Depreciation & Amortisation | 1,104 |
| Profit Before Tax | 7,134 |
| Tax % | - |
| Net Profit / PAT | 5,399 |
| EPS (βΉ) | 64.69 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Dr. Reddy's Laboratories Ltd.this co. | βΉ99.42 K Cr | βΉ23.11 K Cr | 18.40 | 3.15 | 14.34 | 18.6% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |